Related Experiment Video
Updated: May 22, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
Emerging therapies for residual risk
Sanjay Mehra1, Hossein Movahed, Assad Movahed
1Department of Cardiovascular Sciences, East Carolina University Brody School of Medicine, Greenville, NC, USA.
Insights
Statins significantly cut cardiovascular events, but residual risk persists. This review explores new therapies to address this remaining risk in patients on statin therapy.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Statins are proven to reduce coronary artery disease (CAD) risk.
- Statin therapy lowers major clinical events by 25-40% in high-risk patients.
- Residual cardiovascular risk remains significant despite optimal statin treatment.
Purpose of the Study:
- To review emerging therapies for managing residual cardiovascular risk.
- To investigate novel treatment strategies for patients on concurrent statin therapy.
Main Methods:
- Literature review of emerging cardiovascular therapies.
- Analysis of studies investigating risk reduction in patients on statins.
Main Results:
- Emerging therapies show promise in targeting residual cardiovascular risk.
- Concurrent use of novel agents with statins may further reduce adverse events.
Conclusions:
- Addressing residual risk is crucial for comprehensive cardiovascular disease management.
- Further research into novel therapies is warranted to optimize patient outcomes.
Abstract:
The role of statins in reducing the risk of coronary artery disease is well established. The use of statins in patients at high risk for cardiovascular disease has reduced the incidence of major clinical events by 25% to 40%. However, despite aggressive statin therapy and the achievement of target low-density lipoprotein cholesterol levels, the residual risk of cardiovascular events remains high. This review investigates emerging therapies to target the residual risk of cardiovascular events with concurrent statin therapy.
More Related Videos
05:08Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
Published on: February 17, 2019
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Related Concept Videos
Treatment Resistant Cancers
Venous Thrombosis III: Interprofessional Care
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Heart Failure VI: Adjunct Therapies
Treatment Resistent Cancers